Skip to main content

Advertisement

SpringerLink
Log in

Bcl-2 antisense therapy in B-cell malignant proliferative disorders

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin’s lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms.v

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies? Semin Hematol 1997, 34(Suppl 5):9–19.

    PubMed  CAS  Google Scholar 

  2. Reed JC: Bcl-2 family proteins? Oncogene 1998 17:3225–3236.

    Article  PubMed  Google Scholar 

  3. Tsujimoto Y, Gorham J, Cossman J, et al.: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining? Science 1985, 229:1390–1393.

    Article  PubMed  CAS  Google Scholar 

  4. Wang HG, Reed JC: Mechanisms of Bcl-2 protein function? Histol Histopathol 1998, 13:521–530.

    PubMed  CAS  Google Scholar 

  5. Lai R, Arber DA, Chang KL, et al.: Frequency of bcl-2 expression in non-Hodgkin’s lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia? Mod Pathol 1998, 11: 864–869.

    PubMed  CAS  Google Scholar 

  6. Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma? Blood 1997, 90:244–251.

    PubMed  CAS  Google Scholar 

  7. Milner AE, Grand RJ, Vaughan AT, et al.: Differential effects of Bcl-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation? Oncogene 1997, 15:1815–1822.

    Article  PubMed  CAS  Google Scholar 

  8. Logsdon MD, Meyn RE Jr, Besa PC, et al.: Apoptosis and the Bcl-2 gene family: patterns of expression and prognostic value in stage I and II follicular center lymphoma? Int J Radiat Oncol Biol Phys 1999, 44:19–29.

    Article  PubMed  CAS  Google Scholar 

  9. Martinka M, Comeau T, Foyle A, et al.: Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma? Clin Invest Med 1997, 20:364–370.

    PubMed  CAS  Google Scholar 

  10. Ramanarayanan J, Chanan-Khan A, Czuczman MS: Genasense Targeting Bcl-2 Protein Expression Enhances the Biological Anti-tumor Activity of Rituximab Against Non-Hodgkins (NHL) Cell Lines and Lymphoma Xenografts. San Diego: American Society of Hematology; 2003.

    Google Scholar 

  11. van de Donk NW, Kamphuis MM, van Dijk M, et al.: Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein? Leukemia 2003, 17:211–219.

    Article  PubMed  CAS  Google Scholar 

  12. Lebedeva I, Stein CA: Antisense oligonucleotides: promise and reality? Annu Rev Pharmacol Toxicol 2001, 41: 403–419.

    Article  PubMed  CAS  Google Scholar 

  13. Liu Q, Gazitt Y: Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells? Blood 2003, 101: 4105–4114. This paper addresses the issue reversal of chemoresistance by downregulation of Bcl-2 oncoprotein. Multiple myeloma cells resistant to standard therapies were pretreated with oblimersen at clinically relevant doses and, thereafter, exposed to dexamethasone or chemotherapeutic agents. Pretreatment with oblimersen resulted in potentiation of therapy-induced apoptosis in drug-resistant myeloma cell line and in freshly isolated myeloma cells from patients.

    Article  PubMed  CAS  Google Scholar 

  14. Zhang Y, Shen WL: Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide? Cell Biol Int 2003, 27:953–958.

    Article  PubMed  CAS  Google Scholar 

  15. Zhang Y, Lei XY: Effect of bcl-2 antisense oligodeoxynucleotides on drug sensitivity of leukemic cells? Hematol J 2003, 4:187–197.

    Article  PubMed  CAS  Google Scholar 

  16. Auer R, Corbo M: Bcl-2 antisense (Genasense) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells [abstract]? Blood 2001, 98(Suppl 1):808a.

    Google Scholar 

  17. Pepper C, Hooper K, Thomas A, et al.: Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells? Leuk Lymphoma 2001, 42:491–498. This paper highlights the clinical importance of downregulation of Bcl-2 protein in patients with CLL and addresses the issue of chemosensitization by oblimersen to a conventional chemo-therapeutic approach. The increased cytotoxicity noted in this paper is proof of the concept that downregulation of the apoptosis regulatory protein Bcl-2 can set the stage for an enhanced antitumor activity of conventional chemotherapy.

    Article  PubMed  CAS  Google Scholar 

  18. van de Donk NW: G3139, a Bcl-2 Antisense Oligodeoxynucle-otide, Induces Clinical Responses in VAD-refractory Myeloma. San Diego: American Society of Hematology; 2003.

    Google Scholar 

  19. Czuczman M: Pathways Involved in the Emergence of Resis-tance to Rituximab in Non-Hodgkin’s Lymphoma (NHL) Cell Lines. San Diego: American Society of Hematology; 2003.

    Google Scholar 

  20. O’Connor O: Oblimersen (Bcl-2 Antisense) Enhances the Antitumor Activity of Bortezomib (Bor) in Multiple Myeloma (MM) and Non-Hodgkin’s Lymphoma (NHL). San Diego: American Society of Hematology; 2003. This is the first report that presents preclinical rationale for evaluating the combination of Bcl-2 antisense with a novel biologic agent. The preclinical data presented in this report suggest that downregulating Bcl-2 in lymphoid malignancies (lymphoma and multiple myeloma) may augment the clinical efficacy of proteasome inhibitor ie, bortezomib).

    Google Scholar 

  21. Frankel SR: Oblimersen sodium (G3139 Bcl-2 anti-sense oligonucleotide) therapy in Waldenström’s macroglobulinemia: a targeted approach to enhance apoptosis? Semin Oncol 2003, 30:300–304.

    Article  PubMed  CAS  Google Scholar 

  22. Jansen B, Wacheck V, Heere-Ress E: Clinical, pharmacologic and pharmacodynamic study of Genasense (G3139, Bcl-2 antisense oligonucleotide) and decarbazine (DTIC) in patients with malignant melanoma. San Francisco: American Society of Clinical Oncology; 2001.

    Google Scholar 

  23. Rai K: Genasense (Bcl-2 Antisense) Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Phase 1 and 2 Results. Philadelphia: American Society of Hematology; 2002.

    Google Scholar 

  24. Badros AZ: Phase I/II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Patients with Relapsed Multiple Myeloma. San Diego: American Society of Hematology; 2003.

    Google Scholar 

  25. Iqbal J, Horsman DE, Rosenwald A, et al.: Bcl-2 Translocation Defines a Subset of DLBCL with Germinal Center B-Cell-Like Gene Expression Profiles and Preferential Expression of a Set of Genes. San Diego: American Society of Hematology; 2003.

    Google Scholar 

  26. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling? Nature 2000, 403:503–511.

    Article  PubMed  CAS  Google Scholar 

  27. Waters JS, Webb A, Cunningham D, et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma? J Clin Oncol 2000, 18:1812–1823. This is the first reported clinical study exploring the role of Bcl-2 antisense therapy in patients with malignant lympho-proliferative disorders.

    PubMed  CAS  Google Scholar 

  28. Leonard J: Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Chicago: American Society of Clinical Oncology; 2003.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Lymphoma/Myeloma Section, Roswell Park Cancer Institute, Elm and Carlton Streets, 14263, Buffalo, NY, USA

    Asher Chanan-Khan MD

Authors
  1. Asher Chanan-Khan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myron S. Czuczman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chanan-Khan, A., Czuczman, M.S. Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Curr. Treat. Options in Oncol. 5, 261–267 (2004). https://doi.org/10.1007/s11864-004-0017-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-004-0017-3

Keywords

Search

Navigation